We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has approved Genentech and Biogen Idec’s cancer drug Rituxan for the treatment of rheumatoid arthritis (RA), which could open a new market for the world’s top-selling cancer drug.